A Pragmatic Protocol for I-131 rhTSH-Stimulated Ablation Therapy in Patients With Renal Failure

Aa, Driedger; Quirk, Sarah; McDonald, Timothy J.; Ledger, Séadna; Gray, D.; Wall, William; Yoo, Juhyun

doi:10.1097/01.rlu.0000227013.36421.ce

Cited by 14 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are three approaches to 131 I therapy: empiric fixed amounts, therapy determined by the upper bound limit of blood and body dosimetry, and quantitative tumor dosimetry (335). Dosimetric methods are often reserved for patients with distant metastases or unusual situations such as renal insufficiency (336,337) or when therapy with rhTSH stimulation is deemed necessary. Comparison of outcome among these methods from published series is difficult (334).…”

Section: Algorithm For Management Of Dtc Six To Twelve Months After Rmentioning

confidence: 99%

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Cooper

Doherty

Haugen

et al. 2009

Thyroid

6,171

5,487

View full text Add to dashboard Cite

show abstract

Section: Algorithm For Management Of Dtc Six To Twelve Months After Rmentioning

confidence: 99%

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Cooper

Doherty

Haugen

et al. 2009

Thyroid

6,171

5,487

View full text Add to dashboard Cite

show abstract

“…After a full-text screening we excluded another 31 studies for various reasons: they gave no relevant information on dosing or aspects related to dosing ( n = 18), they addressed only the radiation safety of staff ( n = 5), described renal imaging ( n = 5), or were review ( n = 3). A total of 34 studies remained for inclusion in this systematic review (Akers et al 2016 ; Aktaş et al 2008 ; Alevizaki et al 2006 ; Bhat et al 2017 ; Courbon et al 1997 , 2006 ; Culpepper et al 1992 ; Daumerie et al 1996 ; Demko et al 1998 ; Driedger et al 2006 ; El-Zeftawy et al 2017 ; Fofi et al 2013 ; Holst et al 2005 ; Howard and Glasser 1981 ; Jiménez et al 2001 ; Kaptein et al 2000 ; Kode et al 2017 ; Laffon et al 2008 ; Magné et al 2002 ; McKay and Malaroda 2019 ; McKillop et al 1985 ; Mello et al 1994 ; Minamimoto et al 2007 ; Miyasaka et al 1997 ; Morrish et al 1990 ; Pahlka and Sonnad 2006 ; Sinsakul and Ali 2004 ; Tobes et al 1989 ; Toriihara et al 2015 ; Toubert et al 2001 ; Vermandel et al 2020 ; Wang et al 2003 ; Willegaignon et al 2010 ; Yeyin et al 2016 ). The selection process is illustrated in a PRISMA flow diagram (Fig.…”

Section: Resultsmentioning

confidence: 99%

Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

Schreuder

Romijn

Jager

et al. 2021

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background Patients with chronic kidney disease (CKD) may need to have their radiopharmaceutical dosage adjusted to prevent adverse effects and poor outcomes, but there are few recommendations on radiopharmaceutical dosing for this group of patients. The aim of this study is to provide an overview of the available information on radiopharmaceutical dose recommendations for patients with CKD. Methods We performed a systematic literature review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We conducted a literature search in the MEDLINE (PubMed) and Embase databases and screened potentially relevant studies using inclusion and exclusion criteria. We independently assessed the included observational studies’ methodologies and extracted relevant data. Results Of the 5795 studies first identified, 34 were included in this systematic review. These studies described three radiopharmaceuticals: [131I]sodium iodine, [18F]fludeoxyglucose, and [131I]iobenguane. Twenty-nine studies (85.3%) reported data on patients with CKD stage 5, while only three studies mentioned CKD patients in other stages (8.8%). Conclusion We found no consistent recommendations for radiopharmaceutical dosing in patients with CKD. Although some studies do mention dosing difficulties in patients with CKD, information is available for only a few radiopharmaceuticals, and recommendations are sometimes contradictory. Further research on radiopharmaceutical dosing in patients with CKD is needed to determine whether these patients require specific dosing, especially for therapeutic radiopharmaceuticals where a non-optimised dose may lead to an increased risk of toxicity for non-targeted organs. Including patients with CKD in studies and providing specific information about dosing in these patients should be a priority for the radiopharmaceutical community.

show abstract

“……Dosimetric methods are often reserved for patients with distant metastases or unusual situations such as renal insufficiency [4, 5] or when therapy with rhTSH stimulation is deemed necessary.…No prospective randomized trial to address the optimal therapeutic approach has been published.…In the future, the use of 123 I or 131 I with modern SPECT/CT or 124 I PET-based dosimetry may facilitate whole-body and lesional dosimetry [6, 7]. In the treatment of locoregional or metastatic disease, no recommendation can be made about the superiority of one method of RAI administration over another (empiric high dose vs. blood and/or body dosimetry vs. lesional dosimetry.)…”

Section: Introductionmentioning

confidence: 99%

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

Sgouros

Hobbs

Atkins

et al. 2011

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.

show abstract

A Pragmatic Protocol for I-131 rhTSH-Stimulated Ablation Therapy in Patients With Renal Failure

Abstract: Dosimetry performed on euthyroid dialysis patients permits I-131 dose selection and avoids the additional morbidity of hypothyroidism.

Cited by 14 publications

References 14 publications

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

Contact Info

Product

Resources

About